Uveitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Noninfectious Uveitis–Posterior Segment
Most vision loss from uveitis stems from persistent inflammation in the posterior segment of the eye. While noninfectious anterior uveitis is usually managed effectively with topical steroids, noninfectious uveitis affecting the posterior segment (NIU-PS) is harder to treat because it generally does not respond to topical therapy. Corticosteroids are the cornerstone of management, but the use of other immunomodulatory agents—particularly tumor necrosis factor (TNF)-alpha inhibitors—has expanded. This claims analysis offers manufacturers of existing therapies and emerging agents real-world insights into evolving treatment patterns for NIU-PS.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed NIU-PS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NIU-PS patients?
- How have the intravitreal corticosteroid implants Yutiq and Ozurdex been integrated into the treatment algorithm, and what is their source of business?
- What percentage of NIU-PS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of NIU-PS patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Corticosteroids, including intravitreal implants, antimetabolites, TNF-alpha inhibitors, and ophthalmic non-steroidal anti-inflammatory drugs
Key analyses provided:
Brand / therapy usage across the longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flow
Product Description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
